Pterin abnormalities in dystonia: a metabolic marker with therapeutic implications.
LeWitt
P A
PA
National Institutes of Health, Bethesda, Maryland 20205.
Miller
L P
LP
Levine
R A
RA
Lovenberg
W
W
Newman
R P
RP
Papavasiliou
A
A
Rayes
A
A
Eldridge
R
R
Burns
R S
RS
D000328:Adult; D001708:Biopterins / Q000031:analogs & derivatives / Q000134:cerebrospinal fluid / Q000627:therapeutic use; D002490:Central Nervous System / Q000378:metabolism; D004421:Dystonia / Q000134:cerebrospinal fluid / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008875:Middle Aged; D019798:Neopterin; D011622:Pterins / Q000134:cerebrospinal fluid / Q000378:metabolism*
D011622:Pterins; D001708:Biopterins; D006897:Hydroxyindoleacetic Acid; D019798:Neopterin; C003402:sapropterin; D006719:Homovanillic Acid